COVID-19 Staff Testing of Antibody Responses Study (Co-Stars)

NHS Foundation Trust

Status: Completed

Conditions: SARS-CoV-2 Infection

Treatments: Other: Standardised questionnaires; Other: Blood test

Study type: Observational

Funder types: Other

Identifiers

NCT04380896

20CB17

Details and patient eligibility

About

This study will perform prospective repeated serological antibody testing on a cohort of at least 1000 healthcare workers at Great Ormond Street Hospital. Within this cohort, a subset of 150-250 staff members with confirmed (PCR positive) SARS-CoV-2 disease will be followed with intensive monthly testing for 6 months to determine whether antibody levels in the blood are maintained or decrease during this time. All 1000 recruited healthcare workers will be followed 6-monthly

Full description

A total of 250 healthcare workers are currently off sick with symptoms of SARS-CoV-2 infection (COVID-19) while 99 additional members of staff have been diagnosed with confirmed SARS-CoV-2 at Great Ormond Street Hospital. As a consequence, all routine surgery, out-patient activity and day cases have been postponed or cancelled altogether. It is therefore critical for us to understand whether or not this disease will continue to threaten staff health or whether natural infection will give rise to long lasting immunity.

This is a 2-arm prospective cohort study recruiting at least 1000 healthcare workers at GOSH over 6 years.Staff will be recruited and coordinated from each department to be representative of the full diversity of healthcare workers at the Trust. The age distribution of the participants will be monitored on a weekly, basis against the known age distribution of the hospital to ensure that the sample is representative.

Trust communications team will send an all staff email to inform them about this research project asking them to get in touch with the study team if they wish to participate and they meet the basic eligibility criteria. Potential participants will be asked voluntarily to attend a face to face appointment in person (or if preferred by telephone or 1:1 video teleconference meeting) to enable trained study staff to seek informed consent before they enter the study. Informed consent will be undertaken by study staff who are Good Clinical Practice trained, Human Tissue Act trained, study trained, GOSH consent trained and registered in the study log.

The consent process will specifically cover the reason for the study, the storage of samples and agreement for future samples to be tested once improved testing is made available. Once the member of staff has provided informed consent, they will be asked to undertake an online questionnaire in which they will record demographic details including age, sex, email address and telephone contact for results and coordinating follow up. The questionnaire will also record details of SARS-CoV-2 like symptoms, contact with SARS-CoV-2, pre-existing co-morbidities and medication or treatments that may interfere with serological testing.

After providing informed consent, the staff members then be asked attend the study phlebotomy testing clinic. Appointments will be 20 minutes in length but actual blood sampling for serological testing will be 5-10 minutes to allow plenty of time and space for staff members to be tested to maintain social distancing. A total of 8ml of blood will be stored for testing.

Follow up sampling and questionnaires of approximately 200 staff members with PCR confirmed SARS-CoV-2 infected staff will take place monthly. While follow up of all ~800 asymptomatic staff members will take place 6 monthly. All staff will continue to have access to the GOSH PCR COVID19 testing program (as they do at present). This will enable us to confirm with PCR testing any new (or reinfected) positive staff member with COVID-19 over the duration of the study.

When initially asymptomatic seronegative staff become serologically positive during the course of the study, they will remain under active surveillance but they will switch arms of the study and they will contribute to the active follow up of serologically positive patients.

If staff leave the GOSH NHS trust during the study they will still be eligible to remain in the study and be followed up and we will update their contact details on the follow-up questionnaire.

After the initial intensive phase, all approximately 1000 recruits will be followed 6 monthly for the 6 year duration of the study. Follow-up visits will be arranged following the baseline assessment. The same blood tests 4ml EDTA and 4ml serum will be taken at each follow up appointment as well as the same symptom questionnaire.

Enrollment: 3,502 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria for ARM 1: SARS-CoV-2 Seropositive Cases:

• Healthcare worker at GOSH
• >18 years of age
• ALL have confirmed detectable antibodies to SARS-CoV-2 infection on baseline screen

Then can be recruited into either of the following sub-groups

1. Core Group of PCR Confirmed Cases : Must have symptoms consistent with SARS-CoV-2 infection and SARS-CoV-2 PCR Positive
2. Other SARS-CoV-2 Sero-positives: May have Symptoms consistent with SARS-CoV-2 infection and SARS-CoV-2 PCR Negative cases OR May have no symptoms consistent with SARS-CoV-2 infection and PCR Not Tested cases

Inclusion Criteria for ARM 2: SARS-CoV-2 Seronegative Comparison Group :

• Healthcare worker at GOSH
• >18 years of age
• ALL have confirmed negative antibodies to SARS-CoV-2 infection on baseline screen

Then can be recruited into either of the following Sub-groups:

1. Core Comparison Group: Have not had clinical symptoms consistent with SARS-CoV-2 infection*

2. Other Seronegatives: Have had symptoms of SARS-CoV-2 infection but have been tested and were PCR positive or negative but have not developed antibodies at 21 days

   • Clinical Symptoms for SARS-CoV-2 infection are defined as one of:

1. New and persistent cough 2) Confirmed temperatures of 37.8 and above 3) Anosmia

General Exclusion Criteria :

• <18 years of age
• On immunosuppressive or immunomodulatory medication that may impact test reliability
• Received any blood product including immunoglobulins after October 2019
• Has received convalescent sera as treatment
• Current diagnosis of a malignancy that may impact test reliability
• Those lacking capacity to provide informed consent

Trial design

3,502 participants in 2 patient groups

SARS-CoV-2 Seropositive Cases

Description:

It will be formed of approximately N= 200 to 350 staff members Core Group of PCR Confirmed Cases N \~ 150 to 250: A) Symptoms consistent with SARS-CoV-2 infection and SARS-CoV-2 PCR Positive N \~ 150 to 250 OR Other SARS-CoV-2 Sero-positives N \~ 50 to 100: B) Symptoms consistent with SARS-CoV-2 infection and SARS-CoV-2 PCR Negative cases. OR C) No symptoms consistent with SARS-CoV-2 infection and PCR Not Tested cases

Treatment:

Other: Standardised questionnaires

Other: Blood test

SARS-CoV-2 Seronegative Comparison Group

Description:

It will be formed of approximately N= 800 to 900 staff members Core Comparison Group N \~ 800 A) Have not had clinical symptoms consistent with SARS-CoV-2 infection OR Other Seronegatives N \~ 100 B) Have had sympoms of SARS-CoV-2 infection but have been tested and were PCR positive or negative but have not developed antibodies at 21 days

Treatment:

Other: Standardised questionnaires

Other: Blood test